about
Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk ScoresIs There an Obesity Paradox for Outcomes in Atrial Fibrillation? A Systematic Review and Meta-Analysis of Non-Vitamin K Antagonist Oral Anticoagulant Trials.Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry.Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study.Asymptomatic peripheral artery disease and antiplatelet management.Impact of sex and gender on the efficacy of antiplatelet therapy: the female perspective.Relationship between atrial fibrillation and cognitive decline in individuals aged 80 and older: A narrative review.Relationship Between Use of Videogames and Sexual Health in Adult Males.Self-reported physical activity and major adverse events in patients with atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry.Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation.A Focused Review of Gender Differences in Antithrombotic Therapy.Carotid plaque detection improves the predictive value of CHA2DS2-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study.Balancing thromboembolic and bleeding risk with non-vitamin K antagonist oral anticoagulants (NOACs): A systematic review and meta-analysis on gender differences.Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation.Cerebrovascular disease, associated risk factors and antithrombotic therapy in a population screening cohort: Insights from the Belgian Heart Rhythm Week programme.Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study.Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study.'Real-world' atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase.Relation of female sex to left atrial diameter and cardiovascular death in atrial fibrillation: The AFFIRM Trial.Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry.Secondary Versus Primary Stroke Prevention in Atrial Fibrillation: Insights From the Darlington Atrial Fibrillation Registry.Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial.Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry.Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation.Relationship between carotid intima-media thickness and non valvular atrial fibrillation type.Guideline-Adherent Antithrombotic Treatment Improves Outcomes in Patients With Atrial Fibrillation: Insights From the Community-Based Darlington Atrial Fibrillation Registry.Outcome of octogenarians with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry.Systolic Blood Pressure Visit-to-Visit Variability and Major Adverse Outcomes in Atrial Fibrillation: The AFFIRM Study (Atrial Fibrillation Follow-Up Investigation of Rhythm Management).Effect of L-carnitine on oxidative stress and platelet activation after major surgery.Impact of quality of anticoagulation control on outcomes in patients with atrial fibrillation taking aspirin: An analysis from the SPORTIF trials.Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.Bleeding related to non-vitamin K antagonist oral anticoagulants in emergency department: A "Real-world" snapshot from Southern Italy. On behalf of MIRC-NOAC study group.The dangerous combination of atrial fibrillation and hypertension: An urgent need to handle complexity.Use of statins and adverse outcomes in patients with atrial fibrillation: An analysis from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) general registry pilot phase.Erratum to: medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study.Antidotes to non-vitamin K oral anticoagulants: necessary or not?Old And New Oral Anticoagulants In Management Of Atrial Fibrillation: A Double-Edged Sword For Women.Restarting oral anticoagulant therapy after major bleeding in atrial fibrillation: A systematic review and meta-analysis.Ankle-Brachial Index and cardiovascular events in atrial fibrillation. The ARAPACIS Study.Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2 score.
P50
Q29544821-106C1B92-FD3C-4ED4-9792-BE33B0E4F537Q30235408-83AEC77B-2555-46A4-946B-5F5633BB64B7Q33720574-ADE80D79-7568-4D69-823C-2D11134A4D86Q35640209-774A67CC-4A27-4DC8-8873-2C5BEDAB1E63Q38242128-6B354833-3B2A-4F8D-8013-E6D8FA6C27C4Q38271138-6C07E2FC-B9D3-4CB5-B035-4C21C2DC127BQ38627414-01FFEF51-FE27-48B3-9996-CC8914BA4F48Q38745811-14EBBC49-3857-4A92-A380-65106D3BDF43Q38826498-66F3BFC6-A065-4988-BD57-DA21384EADCAQ38979562-3045C00E-449F-4D8F-9234-F087860ECADCQ38996555-AEDD9945-8E2E-427B-9267-30225AC3E991Q39021448-6976BFA6-3E42-454A-A90C-D311848F031AQ39023816-9717DB2A-CD50-400C-97A1-ED5163922010Q39111247-A9EBCB4B-D48F-4CA3-9190-C84A991B16CDQ39137981-675CD12A-17D9-4BB1-90D3-7BECC8FA44D7Q39165597-FCEA5A7D-BF64-418A-A33A-746A1D1D0C00Q39721919-44F15D35-7AC6-46AF-9B3C-EBED943D7BCFQ39754700-F9EEB3D3-F712-4EB2-B8FE-5C34C5261F68Q40063527-F48B668D-FA94-472D-92FC-58B2EA4E503BQ40100946-3A2C0FF3-9801-4155-A824-B61CA95ECED2Q40134045-49B48F26-4441-4B15-9921-4C198B0A6472Q40366138-0216089C-FC59-4861-AD05-3FEE9C084C2DQ40484767-B9C55EA8-9EA0-4927-A567-742E57E5F0F7Q40727046-3F54CCB5-90D7-4573-83E8-52911C303A5AQ41565690-9D59AD29-97CA-4422-A555-DA8035056777Q47304402-7D14E051-B9B7-4415-95ED-DE8A2A18B988Q47304863-98772490-EA25-4663-A305-DB1E7649CEFAQ47871715-4FD73E55-F9D8-4634-B3BB-18B2F743D7E9Q48246820-C59A5141-5031-4FFB-8F71-7083FC25FD69Q49714654-FDFEAF69-68CD-48C1-A7D5-8CDB6937CB33Q49787605-AA5BE4AD-4999-4B6E-8B57-3E7B220A8FA9Q50164072-94610436-9A20-42D4-95DD-5F9BF8CD58AAQ50179442-8E8C70CC-A456-4F08-A45C-B1E414466EA6Q50242159-BD482D5D-6447-4BB8-8AC2-D42C839B2D46Q50849789-C39D8B7E-B357-4A08-8A40-B6943B4C8C58Q50963192-9FEA3DE9-FFCF-4DFA-A5E7-499E31F3F195Q51007738-15B0532A-01B5-4D6E-819D-7B45C1F70BAAQ51735757-80711617-6208-4F7F-B473-F63D2A077230Q53220969-BAC05290-1D74-44CC-B239-084712A16567Q53809147-4FC9362E-D3E2-4B5A-8201-156D20B2C4E8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marco Proietti
@ast
Marco Proietti
@en
Marco Proietti
@es
Marco Proietti
@nl
Marco Proietti
@sl
type
label
Marco Proietti
@ast
Marco Proietti
@en
Marco Proietti
@es
Marco Proietti
@nl
Marco Proietti
@sl
prefLabel
Marco Proietti
@ast
Marco Proietti
@en
Marco Proietti
@es
Marco Proietti
@nl
Marco Proietti
@sl
P106
P21
P31
P496
0000-0003-1452-2478